In the context of PAH, Galhotra et al. demonstrated that FF administration prevents monocrotaline (MCT)-induced PAH by the reduction in oxidative stress and inflammation, as well as the inhibition of NADPH oxidase (NOX) expression in lung tissue [7]. This evidence concerns the gene FMO5 and pulmonary arterial hypertension.